Abbott Laboratories, Inc. ABT recently announced that the FDA has approved a change of label for its HeartMate 3 left ventricular assist device (LVAD or heart pump). The development, meant exclusively ...
Please provide your email address to receive an email when new articles are posted on . The FDA designated Abbott’s recall of its LVAD communication system as class I, the most serious type. Status of ...
Trialists and journalists, practitioners and bloggers really appreciate a soundly positive trial. MOMENTUM-3, presented at the American College of Cardiology 2018 Annual Scientific Sessions, fit that ...
Pharmacotherapy for advanced heart failure patients with a HeartMate 3 left ventricular assist device (LVAD) is being simplified following US Food and Drug Administration approval of a labeling change ...
BOSTON, MA—The best mean arterial pressure (MAP) range in the first several months after implantation of the HeartMate 3 left ventricular assist device (LVAD) appears to be 85 to 100 mm Hg, according ...
Abbott is communicating to physicians about a field corrective action related to the Heart Mate 3 Left Ventricular Assist Device (LVAD). Abbott notified physicians and global regulatory bodies on ...
Abbott Laboratories announced a class I recall of the Heartmate 3 left ventricular assist system (LVAS) that affects nearly 890 units distributed over the past three years, a move triggered by reports ...
An FDA alert warned of problems with some Mobile Power Units of the HeartMate II and HeartMate 3 left ventricular assist devices. Medtronic's thin OmniaSecure defibrillation lead got FDA approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results